Welcome to our dedicated page for Spruce Biosciences news (Ticker: SPRB), a resource for investors and traders seeking the latest updates and insights on Spruce Biosciences stock.
Spruce Biosciences, Inc. (NASDAQ: SPRB) is a clinical-stage biopharmaceutical company dedicated to pioneering new therapies for rare endocrine disorders. The company's mission is to develop and commercialize novel treatments that address unmet medical needs within this specialized field.
Spruce Biosciences is currently advancing its primary product candidate, tildacerfont. This innovative therapy is being developed to serve as the first non-steroidal treatment designed to significantly improve disease management and lessen the dependency on steroids for patients with classic congenital adrenal hyperplasia (CAH). CAH is a genetic disorder affecting the adrenal glands, leading to an imbalance in hormone production. Tildacerfont aims to address this imbalance, offering a promising alternative for patients who have limited treatment options.
The company has made notable strides in its development programs, with ongoing clinical trials aiming to demonstrate the efficacy and safety of tildacerfont. These efforts are crucial in pushing the boundaries of current endocrine disorder treatments and providing new hope for those affected by these rare conditions.
In addition to its flagship product, Spruce Biosciences actively explores other potential therapies and partnerships to expand its impact in the field of endocrinology. The company’s financial health is supported by strategic investments and collaborations, ensuring robust progress towards its goals.
Spruce Biosciences’ commitment to addressing rare endocrine diseases positions it as a significant player in the biopharmaceutical industry. With a clear focus on innovation and patient care, the company continues to make meaningful advancements in medical science. Stay updated with the latest developments from Spruce Biosciences to learn more about its ongoing projects and clinical trials.
Spruce Biosciences (Nasdaq: SPRB) has published results from two Phase 2 clinical studies of tildacerfont for treating classic congenital adrenal hyperplasia (CAH). The studies demonstrated tildacerfont's ability to significantly reduce key hormone levels, including ACTH and androstenedione, particularly in patients with poor disease control. In 60% of cases, normalization of ACTH was observed. The findings support ongoing late-stage trials (CAHmelia-203 and CAHmelia-204) aimed at further assessing tildacerfont's efficacy and its potential to reduce glucocorticoid dosage.
Spruce Biosciences, Inc. (Nasdaq: SPRB) presented promising data from its Phase 2 clinical trial of tildacerfont for treating classic congenital adrenal hyperplasia (CAH) at the 23rd European Congress of Endocrinology. The open-label study showed significant reductions in disease-driving hormones such as ACTH, 17-OHP, and A4 in patients with poor disease control, achieving up to 84% reduction in ACTH levels. Notably, 60% of patients experienced normalization of ACTH levels without increasing steroid doses. The ongoing CAHmelia program aims to further evaluate the treatment's potential to reduce glucocorticoid usage.
Spruce Biosciences (Nasdaq: SPRB), a biopharmaceutical company, announced that CEO Richard King will participate in a virtual fireside chat at the RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 5:25 PM EDT. Interested parties can access the live webcast through the company's investor relations website and an archived replay will be available for 30 days post-event. Spruce is focused on developing therapies for rare endocrine disorders, including its product candidate tildacerfont, aimed at treating classic congenital adrenal hyperplasia and a specific form of polycystic ovary syndrome.
Spruce Biosciences (Nasdaq: SPRB) reported its first-quarter financial results for 2021, highlighting advancements in therapies for rare endocrine disorders. The company has $148.6 million in cash, enabling it to progress its clinical trials, including the Phase 2 program for pediatric classic congenital adrenal hyperplasia (CAH). R&D expenses rose to $6.7 million, while G&A expenses climbed to $3.1 million, resulting in a net loss of $9.9 million. The company plans to submit an IND for polycystic ovary syndrome and initiate critical trials later in the year.
Spruce Biosciences, Inc. (Nasdaq: SPRB) reported its Q4 and 2020 financial results, marking a transformative year in developing therapies for rare endocrine disorders.
Key updates include the initiation of the CAHmelia program for classic congenital adrenal hyperplasia and plans for Phase 2 trials in pediatric classic CAH and PCOS. The company has $157.2 million in cash, enhancing its ability to fund ongoing clinical studies. R&D expenses rose significantly to $23.9 million, with a net loss of $29.5 million reported for the year.
Spruce Biosciences (Nasdaq: SPRB) presented promising results from its Phase 2 trials of tildacerfont for treating congenital adrenal hyperplasia (CAH) at the Endocrine Society’s 2021 Annual Meeting. Data showed significant reductions in key biomarkers: 84% in ACTH, 80% in 17-OHP, and 79% in A4 levels after 12 weeks. The drug was well tolerated, with no new safety concerns. Tildacerfont aims to be the first non-steroidal therapy for CAH, highlighting a significant milestone for patients who have lacked novel treatments for decades.
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company, announced that it will present data from its Phase 1 and 2 trials of tildacerfont for classic congenital adrenal hyperplasia (CAH) at the ENDO 2021 Annual Meeting from March 20-23. Key presentations include results from a 12-week Phase 2 trial and assessments of steroid hormones during the study. Tildacerfont aims to provide a novel non-steroidal therapy, addressing a significant unmet need in CAH, which has lacked new treatments for about 50 years.
Spruce Biosciences (Nasdaq: SPRB), a late-stage biopharmaceutical company, has announced participation in two investor conferences. CEO Richard King will engage in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 24 at 9:00am PST. Additionally, he will take part in a panel discussion on March 2 at the 41st Cowen Annual Healthcare Conference at 11:10am PST. Interested parties can access live webcasts on the company’s website, with replays available for 30 days.
Spruce Biosciences (Nasdaq: SPRB) announced its focus on advancing the CAHmelia program for tildacerfont aimed at treating adults with classic congenital adrenal hyperplasia (CAH). The company plans to initiate a Phase 2 study for pediatric CAH and a rare form of polycystic ovary syndrome (PCOS) in 2021. With approximately $157 million in cash, it aims for major milestones including potential new drug applications. Spruce also bolstered its patent portfolio, extending exclusivity through 2038.
Spruce Biosciences (Nasdaq: SPRB) announced its inclusion in the Russell 2000®, 3000®, and Microcap® Indexes effective December 21, 2020, following quarterly additions by Russell. CEO Richard King highlighted this milestone as a means to enhance visibility and attract institutional investors. The Russell 2000® Index represents around 10% of the total market capitalization of the Russell 3000®. Russell indexes are utilized widely by investment managers, with around $9 trillion in assets tracked against them, indicating a significant recognition for Spruce Biosciences.
FAQ
What is the current stock price of Spruce Biosciences (SPRB)?
What is the market cap of Spruce Biosciences (SPRB)?
What is Spruce Biosciences, Inc. focused on?
What is tildacerfont?
What are classic congenital adrenal hyperplasia (CAH) and its symptoms?
How is Spruce Biosciences contributing to medical science?
What is the significance of tildacerfont in treating CAH?
Are there ongoing clinical trials for tildacerfont?
How does Spruce Biosciences support its financial health?
What partnerships does Spruce Biosciences have?
Where can I find the latest news about Spruce Biosciences?
What makes Spruce Biosciences a significant player in its industry?
